logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Gonadotropin Releasing Hormone Receptor Antagonist class drugs

    FiltersReset Filters
    5 results

    • firmagon

      (Degarelix)
      Ferring Pharmaceuticals Inc.
      Usage: FIRMAGON® is indicated for the treatment of patients with advanced prostate cancer.

    • myfembree

      (relugolix, estradiol hemihydrate, and norethindrone acetate)
      Sumitomo Pharma America, Inc
      Usage: MYFEMBREE is indicated for managing heavy menstrual bleeding due to uterine leiomyomas and for moderate to severe pain associated with endometriosis in premenopausal women. Its use should be limited to 24 months to mitigate the risk of irreversible bone loss.

    • orgovyx

      (relugolix)
      Sumitomo Pharma America, Inc
      Usage: ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.

    • oriahnn

      (Elagolix and Estradiol and Norethisterone)
      AbbVie Inc.
      Usage: ORIAHNN is indicated for managing heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Use is limited to 24 months due to the risk of potential irreversible bone loss.

    • orilissa

      (Elagolix)
      AbbVie Inc.
      Usage: ORILISSA is indicated for managing moderate to severe pain related to endometriosis. Use duration should be limited based on dosage and the patient's coexisting conditions.